GLP-1 Microdosing Before IVF: Weight Loss, Pregnancy Rates, and the Two-Month Washout

Many fertility clinics set a BMI ceiling before they will start a cycle, and some patients arrive having already been told to lose weight first. A weekly GLP-1 injection looks like an obvious shortcut. Some people go further and ask whether a small maintenance dose could keep the appetite effect going right up to egg retrieval.

This article covers what is actually known about using a GLP-1 before IVF: how much weight matters for IVF outcomes, what happened when trials tried weight loss first, what the liraglutide and semaglutide fertility studies found, and what the drug labels say about stopping before pregnancy. The short version is that the weight-loss case is real and the IVF-outcome case is unproven.

Does body weight change IVF success?

Yes, and the effect is consistent across large datasets. Sermondade and colleagues pooled 21 studies in Human Reproduction Update (2019) and found that women with obesity, defined as a BMI of 30 or more, had a lower probability of live birth after IVF than women with a BMI of 18.5-24.9. The risk ratio was 0.85, with a narrow confidence interval of 0.82-0.87. The outlook was worse again when obesity came together with polycystic ovary syndrome (PCOS).

Tang and colleagues (J Assist Reprod Genet, 2021) looked at the shape of that relationship. Each 5-unit rise in BMI carried a relative risk of 0.93 for live birth and 1.09 for miscarriage. The live birth curve was fairly flat from a BMI of 16 to 30, while clinical pregnancy fell sharply above 30. Miscarriage risk was lowest at a BMI of 22-25. For a person well below 30, the IVF-outcome argument for weight loss is weak to begin with.

Does losing weight before IVF raise the chance of a baby?

The best-known randomized trial says not necessarily. Sermondade's own review ended by saying that whether weight loss reverses the effect "should be further evaluated." The LIFEstyle trial, led by Mutsaerts and published in the New England Journal of Medicine in 2016, tested exactly that.

Women in the lifestyle group lost 4.4 kg on average against 1.1 kg in the control group, and 22% dropped out of the program. The main outcome, a healthy singleton born vaginally at term, happened in 27% of the lifestyle group and 35% of the prompt-treatment group (relative risk 0.77). The lifestyle group did have more natural conceptions leading to ongoing pregnancy, 26% versus 16%. Time spent losing weight is time not spent in treatment, and for people whose fertility is declining with age, that trade matters.

What happened when a trial added liraglutide before IVF?

One small pilot trial found much higher IVF pregnancy rates, and it is the study most often quoted on this topic. Salamun and colleagues (European Journal of Endocrinology, 2018) enrolled 28 women with obesity and PCOS who had not responded to first-line fertility treatment. Their mean BMI was 36.7. Half took metformin 1000 mg twice daily, and half took the same metformin plus what the authors called low-dose liraglutide, 1.2 mg daily, for 12 weeks. Ovarian stimulation started only after a 4-week medication-free period.

Pregnancy per embryo transfer was 85.7% in the combination group and 28.6% with metformin alone. Over 12 months, the cumulative pregnancy rate was 69.2% against 35.7%. The interesting detail is that weight loss was almost identical, 7.5 kg versus 7.0 kg, so the authors suggested liraglutide might act on the endometrium rather than through the scale. With 28 participants, though, a few pregnancies either way would have changed the picture, and no larger trial has repeated it.

Do GLP-1 medicines improve IVF pregnancy rates overall?

When the randomized trials are pooled, GLP-1 therapy improves natural conception in PCOS but shows no clear IVF benefit. Kar and colleagues (Eur J Obstet Gynecol Reprod Biol, 2026) combined three randomized trials with 252 participants that compared GLP-1-based therapy with metformin alone.

The odds ratio for natural pregnancy was 3.10, for overall pregnancy 1.41 (not significant) and for IVF pregnancy 1.01, which is essentially no difference. The authors rated the certainty as moderate for natural pregnancy and low for everything else, and wrote that current evidence is insufficient to draw conclusions about IVF outcomes. None of the trials used live birth as the endpoint.

An earlier meta-analysis by Zhou and colleagues (BMC Endocrine Disorders, 2023) reached the same split with 11 randomized trials and 840 women with PCOS. Natural pregnancy improved (risk ratio 1.72), menstrual cycles became more regular, and IVF pregnancy rates did not differ. Semaglutide data are thinner still. A 2026 review by Alnaimi and colleagues in Clinical Obesity found only one semaglutide trial, in which adding it to metformin raised natural pregnancy to 35% from 15%. For more on the PCOS side, see our article on GLP-1 microdosing, PCOS and insulin.

Could recent semaglutide use lower IVF success?

One real-world study raises that possibility, though it cannot prove cause. Wu and colleagues (Reproductive Biology and Endocrinology, 2026) used a large health-records network to match 1,936 women aged 20-40 with infertility. Women who had used semaglutide within one year before fertility-related care had lower pregnancy and live birth rates than matched women who had not. Miscarriage rates did not differ.

Retrospective records cannot show why. Women prescribed semaglutide may have had more metabolic disease, and the timing of the last dose relative to treatment is not clear from the abstract. The authors themselves called for prospective confirmation. The finding is still a useful counterweight to the assumption that a GLP-1 before IVF can only help.

How long before IVF should you stop a GLP-1?

For semaglutide, the Wegovy label says to stop at least 2 months before a planned pregnancy because of the drug's long half-life. The Wegovy prescribing information gives an elimination half-life of about 1 week and says semaglutide stays in the circulation for about 5 to 7 weeks after the last 2.4 mg dose. A smaller dose clears on the same timetable, since half-life does not depend on dose size.

The Zepbound prescribing information is less specific. It says tirzepatide may cause fetal harm and should be stopped when pregnancy is recognized, without a fixed washout. In practice, fertility clinics set their own stop date relative to stimulation or embryo transfer. The Salamun trial, for comparison, built in a 4-week medication-free gap for liraglutide, which is a daily drug that clears much faster.

Tirzepatide also matters before the cycle starts. Its label says it may weaken oral hormonal contraceptives and advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Our article on birth control on a GLP-1 microdose covers that in detail.

Egg retrieval raises one more safety point. Both the Wegovy and Zepbound labels warn that these drugs may slow stomach emptying, which can lead to complications with general anesthesia or deep sedation, including inhaling stomach contents (pulmonary aspiration). Both labels tell patients to inform their providers before any planned procedure. Anyone using a GLP-1 at any dose, including a microdose, should tell the fertility clinic and the anesthesia team before retrieval.

Is it risky to conceive soon after stopping a GLP-1?

So far the observational data do not show a rise in birth defects, but the evidence is limited. Liu and colleagues (Endocrine Connections, 2026) pooled six studies covering 286,599 women, 43,577 of whom were exposed to a GLP-1 receptor agonist within three months before conception or during pregnancy.

The relative risk for major congenital malformations was 1.02, with a tight confidence interval of 0.96-1.08. Preterm birth (1.09), small for gestational age (0.71) and stillbirth (1.16) were not significantly different either. The authors were careful: given the observational design and limited exposed pregnancies, they wrote, the findings "should not be interpreted as proof of safety." That is why the label washout still applies.

What does this mean for a GLP-1 microdose before IVF?

A microdose before IVF is untested, and the idea of continuing one into a cycle runs against both drug labels. The lowest GLP-1 dose studied before IVF was liraglutide 1.2 mg daily, and even that trial stopped the drug 4 weeks before stimulation. A few points follow from what the evidence does show:

• Weight matters most at a BMI above 30. Tang's data show a fairly flat live birth curve below that, so the case for losing weight first is weakest for people already under it.
• Delay has a cost. In LIFEstyle, the group that lost weight first had fewer healthy term births than the group treated straight away.
• The GLP-1 benefit that holds up in trials is natural conception in PCOS, not IVF success.
• Plan the stop date before the start date. Semaglutide needs at least 2 months off before a planned pregnancy, and clinics may ask for their own window.
• Bring the fertility clinic in early. Whether to pursue weight loss first, and how long to wait after stopping, is a decision for the clinic and the prescriber together.

Frequently asked questions

Clinical references

1. Sermondade N, Huberlant S, Bourhis-Lefebvre V, et al. Female obesity is negatively associated with live birth rate following IVF: a systematic review and meta-analysis. Human Reproduction Update. 2019. doi:10.1093/humupd/dmz011
2. Tang K, Guo Y, Wu L, et al. A non-linear dose-response relation of female body mass index and in vitro fertilization outcomes. Journal of Assisted Reproduction and Genetics. 2021. doi:10.1007/s10815-021-02082-8
3. Mutsaerts MA, van Oers AM, Groen H, et al. Randomized Trial of a Lifestyle Program in Obese Infertile Women. New England Journal of Medicine. 2016. doi:10.1056/NEJMoa1505297. Dutch reprint: Nederlands Tijdschrift voor Geneeskunde. 2016. PMID 27966406
4. Salamun V, Jensterle M, Janez A, et al. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. European Journal of Endocrinology. 2018. doi:10.1530/EJE-18-0175
5. Zhou L, Qu H, Yang L, et al. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocrine Disorders. 2023. doi:10.1186/s12902-023-01500-5
6. Kar E, Yeh J, Efe MA, et al. The effect of glucagon-like peptide-1 receptor agonists versus metformin on pregnancy rates in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized trials. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2026. doi:10.1016/j.ejogrb.2026.115499
7. Alnaimi SJ, Alsugeir DM, Wei L, et al. Weight-Lowering Drugs and Natural Female Fertility: A Systematic Review and Meta-Analysis. Clinical Obesity. 2026. doi:10.1111/cob.70092
8. Wu YC, Hsu JC, Su EC, et al. Impact of semaglutide pretreatment on reproductive outcomes in women with overweight and obesity with infertility: a real-world multicenter cohort study. Reproductive Biology and Endocrinology. 2026. doi:10.1186/s12958-026-01549-6
9. Liu X, Xiong B, Yang R, et al. Periconceptional use of GLP-1 receptor agonists and the risk of major congenital malformations: a systematic review and meta-analysis. Endocrine Connections. 2026. doi:10.1530/EC-26-0280
10. WEGOVY (semaglutide) prescribing information. Novo Nordisk. DailyMed, National Library of Medicine. dailymed.nlm.nih.gov
11. ZEPBOUND (tirzepatide) prescribing information. Eli Lilly and Company. DailyMed, National Library of Medicine. dailymed.nlm.nih.gov